Patient-support Hub services are a vital repository of the patient journey
Cloud computing opens a new array of benefits--and challenges--to data-sharing
As payers seek higher-quality data from real-world treatment settings, the importance of reliable measures becomes critical
Drug sponsors have options in both how the new FDA risk programs are structured and how to execute them
Industry response may be to keep more innovations as trade secrets
In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Often mistakenly considered an afterthought, today’s packaging and delivery systems can powerfully affect the safety, efficacy and commercial success of injectables
The Medical Affairs function can play a vital role in today’s product launch process
Specialty drug market success requires patient-focused and therapy-specific channel and services strategies
Control of costs and accounting during clinical trials is a well-known challenge to sponsors. Tools are available
Discerning how and where products are discounted is an expensive headache for manufacturers
While FDA guidance on appropriate medical communication has evolved, US Dept. of Justice attention the practice is intensifying
A host of evaluation methodologies are defining ‘value’ in drug prices
Data drawn from collaborating sources can benefit the patient journey
Personality assessments identify the traits that enable some pharma researchers to ascend to leadership roles in industry
How to prepare for reporting and utilizing published data for business and compliance purposes
These organizations are encouraged to consider all alternatives when planning their packaging, serialization and validation strategies
The geriatric-dominated LTC market is growing, but has unique constraints